Navigation Links
KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue

Martinsried, Germany, October 01, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it added KinAffinity to its service portfolio. KinAffinity provides invaluable information about a kinase inhibitors selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular proteome and thus overcomes the limitations of traditional biochemical assays that only use recombinant proteins.

Kinase inhibitors with favorable pharmaceutical properties are extensively pursued as therapeutics in numerous oncological, neurological and inflammatory indications. However, their development faces significant challenges such as target specificity for the disease-relevant target proteins. Here, KinAffinity provides critical information to select the right lead compound for clinical development.

KinAffinity combines proprietary chemical proteomics methods with state-of-the-art quantitative mass spectrometry (see Sharma et al., Nature Methods 2009). Endogenously expressed, post-translationally modified kinases are enriched by a ready-to-use affinity matrix in the presence of native binding partners and competed with the kinase inhibitor of interest. Subsequently, bioinformatic methods are used to reveal the inhibitors quantitative cellular target profile. The inhibitors targets are ranked by their affinities and reported to the customer.

KinAffinity is applicable for type I and type II kinase inhibitors. It facilitates selectivity analysis on an organism level that accounts for differences in protein expression between different cells, as well as their mutational and modification status that might affect drug binding.


KINAXO Biotechnologies GmbH is a privately-held biotechnology company based in Munich/Martinsried, Germany. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, we closely cooperate with several of the Institutes most outstanding scientists in the field of chemical proteomics and quantitative mass spectrometry, namely Dr. Henrik Daub, Prof. Jesper Olsen and Dr. Jrgen Cox. KINAXOs technology portfolio delivers direct insights into a compounds cellular interactions and its mode of action and is routinely applied to decrease drug development times and improve therapeutic strategies. To expand its KinAffinity platform, KINAXO recently received financial funding from the Bavarian Ministry of Economics. The underlying technology was licensed from the Max Planck Society and co-developed by scientists of the Max Planck Institute of Biochemistry and KINAXOs scientists.
KINAXO has several ongoing collaborations with major pharmaceutical and biotechnology companies such as Boehringer Ingelheim, Johnson & Johnson and Bayer, and is financed by European investors BioM, High-Tech Grnderfonds, KfW, the Max Planck Society, and Mountain Partners.


Dr. Jutta Fritz
Head of Technology and Business Development
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
82152 Martinsried, Germany
Phone +49 89 4613363-22

b3c newswire

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. Springer launches SpringerImages
3. ESHRE launches international study of polar body screening
4. Nutricia launches Nutra Neocate, weaning product designed for cows’ milk protein allergy
5. Swiss Initiative in Systems Biology launches new projects
6. Springer launches
7. Springer launches
8. UC Davis launches One Health care for wild mountain gorillas and human neighbors
9. Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner
10. Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner
11. Iowa State chemist synthesizes carbohydrates, launches startup company
Post Your Comments:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology: